Braveheart Bio lists on Nasdaq, focused on new therapies for hypertrophic cardiomyopathy
Summary
Braveheart Bio listed on Nasdaq under the ticker BRVE on August 5, 2026. The biotech company focuses on developing new therapies for hypertrophic cardiomyopathy and related inherited cardiovascular diseases. It plans to use the IPO proceeds to advance its BH-101 candidate through Phase II trials, expand its research team, and improve manufacturing processes. The company also highlights its patents and FDA fast-track status as it moves toward commercialization.
Funding
Amount
None
Total raised
Date
August 5, 2026
Announcement date
Investors
-
Lead investors
Company
braveheart.bio
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected